Novel 3-benzoyl-2-piperazinylquinoxaline derivatives as potential antitumor agents

Journal of Heterocyclic Chemistry

Volumn 43, Issue 3, 2006, Pages 541-548

  Piras, Sandra ^a   Loriga, Mario ^a   Carta, Antonio ^a   Paglietti, Giuseppe ^a   Costi, M Paola ^b   Ferrari, Stefania ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIHYDROFOLATE REDUCTASE; FOLIC ACID; PIPERAZINE DERIVATIVE; PIRITREXIM; QUINOXALINE DERIVATIVE; THYMIDYLATE SYNTHASE; TRIMETREXATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; ULTRAVIOLET SPECTROSCOPY;

EID: 33744966880     PISSN: 0022152X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jhet.5570430304     Document Type: Article

References (25)

1. R. L. Kisliuk, The Biochemistry of Folates. Folate Antagonists as Therapeutic Agents; F. M. Sirotnak, J. J. Burchall, W. D. Ensminger, and J. A. Montgomery, Eds; Academic Press, New York, pp 1-68 (1984).
2. E. M. Barman, and L. M. Werbel, J. Med. Chem., 34, 479 (1991).
3. C. J. Allegra, J. A. Kovacs, J. C. Drake, B. A. Chabner, and H. Masur, J. Clin. Invest., 79, 478 (1987).
4. J. A. Kovacs, C. J. Allegra, J. C. Swan, J. E. Parillo, B. A. Chabner, and H. Masur, Antimicrob. Agents Chemother., 32, 430 (1988).
5. M. Loriga, M. Fiore, P. Sanna, and G. Paglietti, Farmaco, 50, 289 (1995).
6. M. Loriga, M. Fiore, P. Sanna, and G. Paglietti, Farmaco, 51, 559 (1996).
7. M. Loriga, S. Piras, P Sanna, and G. Paglietti, Farmaco, 52, 157 (1997).
8. M. Loriga, P. Moro, P. Sanna, and G. Paglietti, Farmaco, 52, 531 (1997).
9. G. Vitale, P. Corona, M. Loriga, and G. Paglietti, Farmaco, 53, 139 (1998).
10. P. Corona, G. Vitale, M. Loriga, and G. Paglietti, Farmaco, 53, 150 (1998).
11. P. Corona, G. Vitale, M. Loriga, and G. Paglietti, M. P. Costi, Farmaco, 53, 480 (1998).
12. G. Vitale, P. Corona, M. Loriga, and G. Paglietti, Farmaco, 53, 594 (1998).
13. P. Corona, G. Vitale, M. Loriga, and G. Paglietti, Farmaco, 55, 77 (2000).
14. S. Piras, M. Loriga, and G. Paglietti, Farmaco, 57, 1 (2002).
15. M. Loriga, S. Piras, G. Paglietti, M. P. Costi, and A. Venturelli, Farmaco, 58, 51 (2003).
16. S. Alleca, P. Corona, M. Loriga, G. Paglietti, R. Loddo, V. Mascia, B. Busonera, and P. La Colla, Farmaco, 58, 639 (2003).
17. S. Piras, M. Loriga, and G. Paglietti, Farmaco, 59, 185 (2004).
18. E. Kumazawa, K. Hirotani, S. C. Burford, K. Kawagoe, T. Miwa, I. Mitsui, and A. Ejima, Chem. Pharm. Bull., 45, 1471 (1997).
19. J. E. Audia, D. A. Evrard, G. R. Murdoch, J. J. Droste, J. S. Nissen, K. W. Schenck, P. Fludzinsk, V. L. Lucaites, D. L. Nelson, and M. L. Cohen, J. Med. Chem., 39, 2773 (1996).
20. G. Simchen, and G. Siegl, Synthesis, 945 (1989).
21. J. B. Niedrl, and A. Ziering, J. Am. Chem. Soc., 64, 885 (1942).
22. V. D. Romanenko, and S. I. Burmistrow, Chem. Heterocycl. Comp., 138 (1973).
23. Pailer et al. Monatsh. Chem., 93, 1005, (1962).
24. H. Danh, and J. Nussbaum, Helv. Chim. Acta, 52, 1661, (1969).
25. M. R. Boyd, Principles & Practice of Oncology, Vol 3, n°10, (1989).